Health and Fitness Health and Fitness
Thu, January 6, 2011
[ Thu, Jan 06th 2011 ] - Market Wire
Quidel Announces Proposed Common Shares Offering
[ Thu, Jan 06th 2011 ] - Market Wire
Bond Labs Signs Maryland Distributor for Resurrectiona" Anti-Hangover
[ Thu, Jan 06th 2011 ] - Market Wire
Humana Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference
[ Thu, Jan 06th 2011 ] - Market Wire
Cambridge Heart to Present at OneMedForum San Francisco 2011
[ Thu, Jan 06th 2011 ] - Market Wire
Celgene verffentlicht aktuelle Informationen ber Zulassungsverfahren
[ Thu, Jan 06th 2011 ] - Market Wire
Chemed Corporation to Present at the29th Annual J.P. Morgan Healthcare Conference
[ Thu, Jan 06th 2011 ] - Market Wire
Vertex Pharmaceuticals Announces Webcast of its P .. the 29th Annual J.P. Morgan Healthcare Conference
[ Thu, Jan 06th 2011 ] - Market Wire
SurModics and Ramius Reach Agreement Regarding 2011 Annual Meeting of Shareholders
[ Thu, Jan 06th 2011 ] - Market Wire
XIFAXAN® 550 mg Tablets Demonstrated Significant .. Irritable Bowel Syndrome Without Constipation Ac
[ Thu, Jan 06th 2011 ] - Market Wire
Covidien Announces the Availability of Nellcora" .. with Drger Infinity® Acute Care System in Europe
[ Thu, Jan 06th 2011 ] - Market Wire
Celgene annonce le d©p't de soumissions r©glementaires
[ Thu, Jan 06th 2011 ] - Market Wire
Biogen Idec nomina Doug Williams responsabile del .. Steven Holtzman a capo del Corporate Development
[ Thu, Jan 06th 2011 ] - Market Wire
Covidien kondigt beschikbaarheid aan van Nellcora .. met Drger Infinity® Acute Care System in Europa
[ Thu, Jan 06th 2011 ] - Market Wire
Covidien annuncia la disponibilit della tecnologi .. l'Infinity® Acute Care System di Drger in Europa
[ Thu, Jan 06th 2011 ] - Market Wire
Biogen Idec ernennt Doug Williams zum Leiter der .. bteilung und Steven Holtzman zum Leiter der Unter
[ Thu, Jan 06th 2011 ] - Market Wire
Covidien meldet die Verfgbarkeit der Nellcora" Ox .. standteil des Infinity® Acute Care Systems von D
[ Thu, Jan 06th 2011 ] - Market Wire
Biogen Idec stelt Doug Williams aan als hoofd O&O .. n Steven Holtzman als hoofd Corporate Development
Wed, January 5, 2011
[ Wed, Jan 05th 2011 ] - Market Wire
Santarus and Depomed Announce Availability of GLUMETZA 500 mg Tablets
[ Wed, Jan 05th 2011 ] - Market Wire
SuperGen Announces Enrollment of First Patient in .. in Human Trial of SGI-110 in MDS and AML Patients
[ Wed, Jan 05th 2011 ] - Market Wire
ANGIOTECH PHARMACEUTICALS ANNOUNCES NOTICE OF DELISTING FROM THE NASDAQ STOCK MARKET
[ Wed, Jan 05th 2011 ] - Market Wire
Positive Phase II Results with Iniparib (BSI-201) .. ple Negative Breast Cancer Published in The New E
[ Wed, Jan 05th 2011 ] - Market Wire
Medtronic Announces $750,000 in Funding to Support Healthcare Infrastructure Development in Haiti
[ Wed, Jan 05th 2011 ] - Market Wire
Hythiam Announces Catasys Contract with Coventry Health Care, Inc. Unit
[ Wed, Jan 05th 2011 ] - Market Wire
CEO of ARCA biopharma to Speak on Cardiovascular .. Medicine at Personalized Medicine Coalition Confe
[ Wed, Jan 05th 2011 ] - Market Wire
St. Jude Medical Announces Fourth Quarter and Full-Year 2010 Earnings Conference Call
[ Wed, Jan 05th 2011 ] - Market Wire
LabCorp is Scheduled to Present at the 29th Annual J.P. Morgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
LifePoint Hospitals to Participate in 29th Annual J.P. Morgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
Almirall and Forest Announce Positive Results fro .. of Aclidinium Bromide and the Phase IIb Studies w
[ Wed, Jan 05th 2011 ] - Market Wire
AngioDynamics Reports Fiscal 2011 Second Quarter Financial Results
[ Wed, Jan 05th 2011 ] - Market Wire
Alkermesa? Corporate Presentation to be Webcast at the JPMorgan Healthcare Conference

Alkermesa? Corporate Presentation to be Webcast at the JPMorgan Healthcare Conference


Published on 2011-01-05 09:31:01 - Market Wire
  Print publication without navigation


WALTHAM, Mass.--([ BUSINESS WIRE ])--Alkermes, Inc. (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the JPMorgan 29th Annual Healthcare Conference on Monday, January 10, 2011, at 8:00 a.m. PT (11:00 a.m. ET) from the Westin St. Francis Hotel in San Francisco. The presentation may be accessed under the investor relations tab at [ www.alkermes.com ]. The presentation will be archived for 14 days.

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol and opioid dependence and manufactures RISPERDAL® CONSTA® for schizophrenia and bipolar I disorder. Alkermes' robust pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Massachusetts, Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.

Contributing Sources